Skip to content
Clinical Trials – home
GreeceBack to Greece

Clinical trials in Kalamaria – page 54

740 clinical trials in Kalamaria, Greece. Every trial is listed in the EU Clinical Trials Register and updated daily.

GreeceOur site in GreeceΚλινικεσΔοκιμεσ.gr(opens in a new tab)
Kalamaria at a glance
740
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

740 trials in Kalamaria

Open in trial search

Plasma cell myeloma

Not recruiting

Study Comparing Talquetamab, Daratumumab, and Pomalidomide with Drug Combination for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Janssen Cilag International

Study on the Effectiveness and Safety of Iptacopan for Adults with Atypical Hemolytic Uremic Syndrome Not Previously Treated with Complement Inhibitors

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Study of Pembrolizumab for Patients with Early Stage Non-Small Cell Lung Cancer After Surgery and Standard Therapy

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Study Comparing Teclistamab with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma After 1-3 Prior Treatments

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Study of Lurbinectedin and Atezolizumab for Maintenance Therapy in Patients with Extensive-Stage Small-Cell Lung Cancer

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Plasma cell myeloma

Not recruiting

Study of Teclistamab and Lenalidomide as Maintenance Treatment for Newly Diagnosed Multiple Myeloma Patients After Stem Cell Transplantation

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

IgA nephropathy

Not recruiting

Study on Ravulizumab for Adults with Immunoglobulin A Nephropathy (IgAN) to Preserve Kidney Function

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Ravulizumab
  • Sponsor:Alexion Pharmaceuticals Inc.

Psoriasis

Not recruiting

Study Comparing Risankizumab and Deucravacitinib for Adults with Moderate Plaque Psoriasis Eligible for Systemic Therapy

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on the Effectiveness and Safety of Remibrutinib Compared to Teriflunomide for Patients with Relapsing Multiple Sclerosis

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years
  • Substances:Charcoal, Activated
  • Sponsor:Novartis Pharma AG

Study of inavolisib, palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant
  • Sponsor:F. Hoffmann-La Roche AG

Study on the Long-term Safety and Effectiveness of Danicopan with Ravulizumab or Eculizumab for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Danicopan
  • Sponsor:Alexion Pharmaceuticals Inc.

Plasma cell myeloma

Not recruiting

Study Comparing Belantamab Mafodotin with Pomalidomide and Dexamethasone to Bortezomib with Pomalidomide and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Belantamab Mafodotin
  • Sponsor:Glaxosmithkline Research & Development Limited

Other cities in Greece

The busiest research cities in the country

All 48 cities in Greece

Clinical research in Kalamaria

What the registry says about research in the country

01 Cardiovascular Research

Innovative clinical trials focusing on atherosclerotic cardiovascular disease in patients with end-stage kidney disease are being conducted. The research aims to evaluate novel therapeutic approaches for patients undergoing dialysis treatment.

  • Cardiovascular Outcomes
  • Inflammatory Biomarkers
  • Dialysis Patient Care

These studies specifically examine the effectiveness of targeted treatments in reducing C-reactive protein levels, a key marker of inflammation in cardiovascular disease among dialysis patients.

02 Nephrology Studies

Current research explores the intersection of kidney disease and cardiovascular complications, with a particular focus on patients receiving maintenance dialysis treatment.

  • End-Stage Kidney Disease Management
  • Cardiovascular Risk Assessment
  • Treatment Response Monitoring

The trials investigate intravenous therapeutic options designed to improve outcomes for patients with complex cardiovascular and renal conditions.

03 Inflammatory Disease Research

Specialized studies are evaluating the role of inflammation markers in cardiovascular complications among dialysis patients, testing innovative therapeutic approaches.

  • Inflammatory Biomarker Analysis
  • Disease Progression Monitoring
  • Treatment Response Assessment

This research aims to advance our understanding of inflammation's role in cardiovascular disease among patients with kidney failure.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.